# ELEVATE-TN (NCT02475681)

> Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

No report yet. It can be ordered.

- Drugs tested: acalabrutinib plus obinutuzumab; acalabrutinib
- Indication: treatment-naive chronic lymphocytic leukemia

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02475681
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Acerta Pharma BV
- Conditions: Chronic Lymphocytic Leukemia
- Interventions: Acalabrutinib; Obinutuzumab; Chlorambucil
- Enrollment: 535
- Primary outcome: Progression-free Survival by IRC (Independent Review Committee) Assessment in Arm A Compared to Arm B

## Indexed commentary on ELEVATE-TN so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 77
- Podcasts: 58
- X threads: 11
- Bluesky threads: 2
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=elevate-tn-nct02475681

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02475681", "email": "<work email>"}; the inbox owner confirms by the emailed link.